Loading...
Back to narrative

PBYI: 2025 Revenue Guidance Will Fail To Justify Current Optimism

Declining Revenues And Rising Costs Will Harm US Biotechs Future

PBYI logo
PBYI
AnalystConsensusTarget
Not Invested
Published 09 Feb 2025

Update shared on 12 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
94.2%
7D
2.7%

Analysts have modestly adjusted their price target on Puma Biotechnology higher, now seeing slightly improved valuation support in light of stable fair value estimates and marginally lower perceived risk in the companys long term outlook.

What's in the News

  • Puma Biotechnology issued new fourth quarter 2025 guidance, projecting total revenue between $67 million and $70 million and net income of $9 million to $11 million (company guidance).
  • The company raised its full year 2025 outlook, now expecting total revenue of $220 million to $223 million, up from prior guidance of $212 million to $222 million (company guidance).
  • Full year 2025 net income guidance was also increased, with the company now targeting $27 million to $29 million, compared to the previous range of $23 million to $28 million (company guidance).

Valuation Changes

  • Fair Value Estimate: Unchanged at 3.5, indicating a stable assessment of intrinsic value.
  • Discount Rate: Fell slightly from 7.31 percent to 7.29 percent, reflecting a marginally lower perceived risk profile.
  • Revenue Growth: Essentially unchanged at approximately 0.97 percent, suggesting a steady outlook for top line growth.
  • Net Profit Margin: Flat at about 11.02 percent, indicating no material change in expected profitability.
  • Future P/E: Edged down slightly from 9.35x to 9.34x, implying a marginally lower multiple applied to future earnings.

Have other thoughts on Puma Biotechnology?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.